Table 1 Summary characteristics of included studies
Characteristics | n. (22 studies) | % |
|---|---|---|
Publication year | Â | Â |
 2000–2009 | 6 | 27.27 |
 2010–2019 | 12 | 54.55 |
 2020–2023 | 4 | 18.18 |
Study designs | Â | Â |
 Case–control study | 9 | 40.91 |
 Cross-sectional study | 6 | 27.27 |
 Cohort study | 6 | 27.27 |
 Randomized controlled trial | 1 | 4.55 |
Study areas | Â | Â |
Asia | 3 | 13.64 |
 India | 3 | 13.64 |
Africa | 16 | 72.73 |
 Ghana | 3 | 13.64 |
 Kenya | 3 | 13.64 |
 Mali | 2 | 9.09 |
 Uganda | 2 | 9.09 |
 Rwanda | 1 | 4.55 |
 Mozambique | 1 | 4.55 |
 Gabon | 1 | 4.55 |
 Nigeria | 1 | 4.55 |
 Tanzania | 1 | 4.55 |
 Cameroon | 1 | 4.55 |
South America | 3 | 13.64 |
 Brazil | 3 | 13.64 |
Plasmodium species | Â | Â |
 P. falciparum | 19 | 86.36 |
 P. vivax | 3 | 13.64 |
Participants | Â | Â |
 Children | 12 | 54.55 |
 Adults | 4 | 18.18 |
 Children and adults | 4 | 18.18 |
 Pregnant women | 2 | 9.09 |
Methods for malaria | Â | Â |
 Microscopic method | 11 | 50.00 |
 Microscopic method/PCR | 4 | 18.18 |
 Microscopic method/RDT | 5 | 22.73 |
 PCR | 1 | 4.55 |
 Not specified | 1 | 4.55 |
Assays for RANTES | Â | Â |
 Bead-based assay | 16 | 72.73 |
 ELISA | 5 | 22.73 |
 Not specified | 1 | 4.55 |
Blood samples | Â | Â |
 Plasma | 19 | 86.36 |
 Serum | 3 | 13.64 |